Ginkgo Bioworks (DNA) Stock Price, News & Analysis

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" DNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DNA, but not buy additional shares or sell existing shares.
View DNA analyst ratings or view top-rated stocks.

5 analysts have issued twelve-month price targets for Ginkgo Bioworks' stock. Their DNA share price targets range from $1.10 to $3.00. On average, they expect the company's share price to reach $2.20 in the next twelve months. This suggests a possible upside of 131.1% from the stock's current price.
View analysts price targets for DNA or view top-rated stocks among Wall Street analysts.

Ginkgo Bioworks' stock was trading at $1.69 at the start of the year. Since then, DNA shares have decreased by 43.7% and is now trading at $0.9521.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our DNA earnings forecast.

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) released its quarterly earnings data on Thursday, February, 29th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The firm had revenue of $34.76 million for the quarter, compared to the consensus estimate of $40.37 million. Ginkgo Bioworks had a negative net margin of 355.08% and a negative trailing twelve-month return on equity of 48.23%. The firm's quarterly revenue was down 64.6% on a year-over-year basis. During the same period in the prior year, the business posted ($0.04) EPS.

ETFs with the largest weight of Ginkgo Bioworks (NYSE:DNA) stock in their portfolio include VegTech Plant-based Innovation & Climate ETF (EATV), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Genomic Revolution ETF (ARKG), Direxion Moonshot Innovators ETF (MOON), ARK Innovation ETF (ARKK), Robo Global Artificial Intelligence ETF (THNQ), IQ U.S. Mid Cap R&D Leaders ETF (MRND) and Range Cancer Therapeutics ETF (CNCR).

Ginkgo Bioworks issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $215.0 million-$235.0 million, compared to the consensus revenue estimate of $279.6 million.

Ginkgo Bioworks' stock is owned by a number of institutional and retail investors. Top institutional investors include Salem Investment Counselors Inc. (0.22%) and Green Alpha Advisors LLC (0.01%). Insiders that own company stock include Barry Canton, Christian O Henry, Jason R Kelly, Marie E Fallon, Marijn E Dekkers, Mark E Dmytruk, Reshma P Shetty and Shyam Sankar.
View institutional ownership trends.

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.